Bioavailability, pharmacokinetics and tolerability of elvitegravir/emtricitabine/tenofovir disoproxil fumarate/GS 9350 compared with the individual components

Trial Profile

Bioavailability, pharmacokinetics and tolerability of elvitegravir/emtricitabine/tenofovir disoproxil fumarate/GS 9350 compared with the individual components

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2010

At a glance

  • Drugs Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary) ; Cobicistat; Elvitegravir; Emtricitabine; Ritonavir; Tenofovir disoproxil fumarate
  • Indications HIV infections; HIV-1 infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 01 Nov 2010 Results have been published in the Journal of Acquired Immune Deficiency Syndromes.
    • 13 Feb 2009 New trial record.
    • 10 Feb 2009 Results presented at CROI 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top